OSTEOPORE LIMITED — Capital/Financing Update 2021

Sep 15, 2021

==> picture [130 x 44] intentionally omitted <==

ASX RELEASE│OSTEOPORE LIMITED

16 September 2021

Company Announcements Office ASX Limited

By E-Lodgement

Notice of Release from Escrow

In accordance with ASX Listing Rule 3.10A, Osteopore Limited (ASX:OSX) advises that the following securities are due to be released from escrow on 23 September 2021 as follows:-

ASX security code and description	Number of securities
OSXAD: fully paid ordinaryshares	39,230,438
OSXAE: unlisted options expiring30 June 20221	9,700,000

1 unlisted options exercisable at $0.25 each and expiring 30 June 2022.

The Company will seek quotation of 39,230,438 fully paid ordinary shares.

This release has been approved for release by Osteopore’s Company Secretary.

For more information please contact:

Deborah Ho

Company Secretary Osteopore Limited P: +61 8 9482 0500

About Osteopore Limited

Osteopore Ltd, an Australian ASX listed company (OSX) with R&D and manufacturing in Singapore, is the global leader in the manufacture of innovative regenerative implants at commercial scale. By combining biomimetic tissue science with proprietary 3D printing and materials technology, Osteopore produces medical implants to meet the needs of both tissue and bone reconstruction as well as restoration. These bioresorbable implants provide a scaffold for bone regeneration, dissolving predictably over time to leave only natural bone tissue. In collaboration with clinicians and researchers, Osteopore develops and manufactures implants that address unmet clinical needs which improve patient outcomes, enhances lives, and potentially reduces healthcare costs. For more information, visit us at www.osteopore.com

Osteopore Limited (ACN 630 538 957)│ASX:OSX│16 Ord Street, West Perth│+618 9482 0500│www.osteopore.com